ADVANCING MOST-FAVORED-NATION PRICING: Today, President Donald J. Trump announced the second agreement with a major pharmaceutical company, AstraZeneca, to bring American drug prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price).
- The agreement will provide every State Medicaid program in the country access to MFN drug prices on AstraZeneca products, resulting in hundreds of millions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable.
- The agreement ensures foreign nations can no longer use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines AstraZeneca brings to market.
- The agreement requires AstraZeneca to repatriate increased foreign revenue on existing products that AstraZeneca realizes as a result of the President’s strong America First U.S. trade policies for the benefit of American patients.
- The agreement requires AstraZeneca to offer medicines at a deep discount off the list price when selling directly to American patients.
DELIVERING REDUCED COSTS: Today’s actions will result in tangible cost savings to American patients and the healthcare system as a whole.
- 9 million American patients are treated by AstraZeneca medicines and will benefit from the President’s successful negotiation to lower prices.
- The 25 million Americans who suffer from asthma, and the 16 million Americans who suffer from chronic obstructive pulmonary disease (COPD), one of the top ten leading causes of death in the United States, could benefit from these price reductions.
- BEVESPI AEROSPHERE, an inhaler used to treat chronic obstructive pulmonary disease (COPD), will be made available to patients purchasing directly at a discount equal to 654% of the deal price.
- BREZTRI AEROSPHERE, an inhaler used to treat COPD, will be made available to patients purchasing directly at a discount equal to 98% of the deal price.
- AIRSUPRA, an inhaler used to treat asthma symptoms and attacks, will be made available to patients purchasing directly at a discount equal to 96% of the deal price.
INVESTING IN AMERICA TO SECURE PHARMACEUTICAL SUPPLY CHAINS: AstraZeneca is also announcing that it will invest $50 billion in U.S. manufacturing and research and development by 2030.
- The company is building a new facility in Charlottesville, Virginia, which will produce advanced pharmaceutical ingredients to support their chronic disease and oncology pipelines.
- The Virginia facility will create 3,600 highly skilled jobs.
ENDING GLOBAL FREELOADING ON AMERICAN PHARMACEUTICAL INNOVATION: President Trump is taking decisive action to rebalance a system that allows pharmaceutical manufacturers to offer low prices to other wealthy nations while charging Americans significantly higher prices.
- According to recent data, the prices Americans pay for brand-name drugs are more than three times the price other Organization for Economic Cooperation and Development nations pay, even after accounting for discounts manufacturers provide in the U.S.
- The United States has less than five percent of the world’s population, yet roughly 75% of global pharmaceutical profits come from American taxpayers.
- Drug manufacturers benefit from generous research subsidies and enormous healthcare spending by the U.S. Government. Instead of passing that benefit through to American consumers, drug manufacturers then discount their products abroad to gain access to foreign markets and subsidize those discounts through high prices charged in America. Americans are subsidizing drug-manufacturer profits and foreign health systems, both in development and once the drugs are sold.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises for American patients that the political establishment did not believe were possible.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- On September 30, 2025, President Trump announced an agreement with Pfizer to bring MFN prices to American patients.
- President Trump has been relentless in his effort to address the unfair and outrageous prices Americans pay for prescription drugs:
- President Trump: “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home. So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything — four times, five times different.”
Source link
